Researchers are rapidly examining retatrutide, a promising drug created by Eli Lilly, as a significant advance in body reduction . Different than many earlier approaches, retatrutide is a double -action receptor targeting both GLP-1 and GIP, substances that affect satiety and blood glucose regulatio